Publications by authors named "Markus Scheerer"

Claim this Profile

Mentions over time

Mentions by platform

Video Views

659

Total Likes

555

Extended Reach

2,565,224

Social Features

216
T
Temporal Changes in Biomarkers, Functional Status, and Quality of Life Prior to Adverse Clinical Outcomes in Heart Failure With Mildly Reduced or Preserved Ejection Fraction.
Henri Lu, Brian L Claggett, Muthiah Vaduganathan, Akshay S Desai, Pardeep S Jhund, Markus F Scheerer

JACC Heart Fail· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
COmbinatioN effect of FInerenone anD EmpaglifloziN in participants with chronic kidney disease and type 2 diabetes using a UACR Endpoint (CONFIDENCE) trial: baseline clinical characteristics.
Rajiv Agarwal, Jennifer B Green, Hiddo J L Heerspink, Johannes F E Mann, Janet B McGill, Markus F Scheerer

Nephrol Dial Transplant· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Finerenone, chronic obstructive pulmonary disease, and heart failure with mildly reduced or preserved ejection fraction: A prespecified analysis of the FINEARTS-HF trial.
Jawad H Butt, Pardeep S Jhund, Alasdair D Henderson, Brian L Claggett, Akshay S Desai, Markus F Scheerer

Eur J Heart Fail· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and Safety of Finerenone in Heart Failure With Preserved Ejection Fraction: A FINE-HEART Analysis.
John W Ostrominski, Gerasimos Filippatos, Brian L Claggett, Zi Michael Miao, Akshay S Desai, Markus F Scheerer

JACC Heart Fail· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Finerenone and Atrial Fibrillation in Heart Failure: A Secondary Analysis of the FINEARTS-HF Randomized Clinical Trial.
Shingo Matsumoto, Alasdair D Henderson, Pardeep S Jhund, Johann Bauersachs, Ovidiu Chioncel, Markus Florian Scheerer

JAMA Cardiol· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Mode of Death in Patients With Heart Failure With Mildly Reduced or Preserved Ejection Fraction: The FINEARTS-HF Randomized Clinical Trial.
Akshay S Desai, Pardeep S Jhund, Muthiah Vaduganathan, Brian L Claggett, Jonathan W Cunningham, Markus F Scheerer

JAMA Cardiol· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Finerenone Across the Spectrum of Kidney Risk in Heart Failure: The FINEARTS-HF Trial.
John W Ostrominski, Finnian R Mc Causland, Brian L Claggett, Akshay S Desai, Pardeep S Jhund, Markus F Scheerer

JACC Heart Fail· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effects of the Nonsteroidal MRA Finerenone With and Without Concomitant SGLT2 Inhibitor Use in Heart Failure.
Muthiah Vaduganathan, Brian L Claggett, Ian J Kulac, Zi Michael Miao, Akshay S Desai, Markus Florian Scheerer

Circulation· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Finerenone and Kidney Outcomes in Patients With Heart Failure: The FINEARTS-HF Trial.
Finnian R Mc Causland, Muthiah Vaduganathan, Brian L Claggett, Ian J Kulac, Akshay S Desai, Markus F Scheerer

J Am Coll Cardiol· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Finerenone, Obesity, and Heart Failure With Mildly Reduced/Preserved Ejection Fraction: Prespecified Analysis of FINEARTS-HF.
Jawad H Butt, Alasdair D Henderson, Pardeep S Jhund, Brian L Claggett, Akshay S Desai, Markus F Scheerer

J Am Coll Cardiol· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Bidirectional modulation of TCA cycle metabolites and anaplerosis by metformin and its combination with SGLT2i.
Makoto Harada, Jonathan Adam, Marcela Covic, Jianhong Ge, Stefan Brandmaier, Markus F Scheerer

Cardiovasc Diabetol· June 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Metabolic effects of SGLT2i and metformin on 3-hydroxybutyric acid and lactate in db/db mice.
Makoto Harada, Siyu Han, Mengya Shi, Jianhong Ge, Shixiang Yu, Markus F Scheerer

Int J Biol Macromol· April 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Rationale and design of a randomised phase III registration trial investigating finerenone in participants with type 1 diabetes and chronic kidney disease: The FINE-ONE trial.
Hiddo J L Heerspink, Andreas L Birkenfeld, David Z I Cherney, Helen M Colhoun, Linong Ji, Markus F Scheerer

Diabetes Res Clin Pract· October 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
K
Kidney outcomes with finerenone: an analysis from the FIGARO-DKD study.
Luis M Ruilope, Bertram Pitt, Stefan D Anker, Peter Rossing, Csaba P Kovesdy, Markus F Scheerer

Nephrol Dial Transplant· February 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Finerenone in Patients With Chronic Kidney Disease and Type 2 Diabetes by Sodium-Glucose Cotransporter 2 Inhibitor Treatment: The FIDELITY Analysis.
Peter Rossing, Stefan D Anker, Gerasimos Filippatos, Bertram Pitt, Luis M Ruilope, Markus F Scheerer

Diabetes Care· December 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effects of canagliflozin versus finerenone on cardiorenal outcomes: exploratory post hoc analyses from FIDELIO-DKD compared to reported CREDENCE results.
Rajiv Agarwal, Stefan D Anker, Gerasimos Filippatos, Bertram Pitt, Peter Rossing, Markus F Scheerer

Nephrol Dial Transplant· June 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Finerenone in Predominantly Advanced CKD and Type 2 Diabetes With or Without Sodium-Glucose Cotransporter-2 Inhibitor Therapy.
Peter Rossing, Gerasimos Filippatos, Rajiv Agarwal, Stefan D Anker, Bertram Pitt, Markus F Scheerer

Kidney Int Rep· January 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-term efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes: pooled 52-week outcomes from the DEPICT-1 and -2 studies.
Moshe Phillip, Chantal Mathieu, Marcus Lind, Eiichi Araki, Paolo di Bartolo, Markus Florian Scheerer

Diabetes Obes Metab· February 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Add-on therapy with dapagliflozin under full closed loop control improves time in range in adolescents and young adults with type 1 diabetes: The DAPADream study.
Torben Biester, Ido Muller, Thekla von dem Berge, Eran Atlas, Revital Nimri, Markus F Scheerer

Diabetes Obes Metab· February 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
Validation of Candidate Phospholipid Biomarkers of Chronic Kidney Disease in Hyperglycemic Individuals and Their Organ-Specific Exploration in Leptin Receptor-Deficient db/db Mouse.
Jialing Huang, Marcela Covic, Cornelia Huth, Martina Rommel, Jonathan Adam, Markus F Scheerer

Metabolites· February 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Machine Learning Approaches Reveal Metabolic Signatures of Incident Chronic Kidney Disease in Individuals With Prediabetes and Type 2 Diabetes.
Jialing Huang, Cornelia Huth, Marcela Covic, Martina Troll, Jonathan Adam, Markus F Scheerer

Diabetes· December 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Dapagliflozin effects on haematocrit, red blood cell count and reticulocytes in insulin-treated patients with type 2 diabetes.
Jens Aberle, Markus Menzen, Sebastian M Schmid, Christoph Terkamp, Elmar Jaeckel, Markus F Scheerer

Sci Rep· December 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Benefit/risk profile of dapagliflozin 5 mg in the DEPICT-1 and -2 trials in individuals with type 1 diabetes and body mass index ≥27 kg/m.
Chantal Mathieu, Paresh Dandona, Andreas L Birkenfeld, Troels Krarup Hansen, Nayyar Iqbal, Markus Florian Scheerer

Diabetes Obes Metab· November 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effect of dapagliflozin as an adjunct to insulin over 52 weeks in individuals with type 1 diabetes: post-hoc renal analysis of the DEPICT randomised controlled trials.
Per-Henrik Groop, Paresh Dandona, Moshe Phillip, Pieter Gillard, Steven Edelman, Markus F Scheerer

Lancet Diabetes Endocrinol· October 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis